Name: SX-682
Brand: Selleck Chemicals
SKU: S8947
Availability: InStock
Rating: 5 (4 reviews)

Jump to

Quality Control

Batch: S894701 DMSO]93 mg/mL]false]Ethanol]93 mg/mL]false]Water]˂1 mg/mL]false Purity: 98.66%

Cited in Nature Medicine for its top-tier quality
COA
NMR
SDS/MSDS
Datasheet

98.66

Related Targets	PD-1/PD-L1 STING AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor
Other CXCR Inhibitors	AZD5069 SB 225002 Reparixin (Repertaxin) WZ811 Navarixin (SCH-527123) LIT-927 AMG 487 SB 265610 LY2510924 UNBS5162

Solubility

In vitro
Batch:

DMSO : 93 mg/mL (199.05 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 93 mg/mL

Water : ˂1 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.650mg/ml (9.95mM)	Taking the 1 mL working solution as an example, add 50 μL of 93 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.660mg/ml (1.41mM)	Taking the 1 mL working solution as an example, add 50 μL of 13.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	467.20	Formula	C₁₉H₁₄BF₄N₃O₄S	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1648843-04-2	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	B(C1=C(C=C(C=C1)OC(F)(F)F)CSC2=NC=C(C=N2)C(=O)NC3=CC=C(C=C3)F)(O)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	CXCR1 CXCR2
In vivo	Whole tumor accumulation of CXCL1 in vivo in MOC1 and LLC tumors is significantly greater than oral mucosa and normal lung, respectively, and not diminished with SX-682 treatment. Plasma accumulation of CXCL1 is greater in tumor-bearing mice compared with naive for both models and increases following this compound treatment. Treatment of mice bearing MOC1 or LLC tumors with this chemical beginning 10 or 20 days after tumor initiation does not alter CXCR1 or CXCR2 expression on tumor cells in vivo. Following in vivo this compound treatment, tumor PMN-MDSC expression of cell surface TGF-β or superoxide dismutase 1/2 genes, responsible for the generation of H₂O₂, is not significantly altered.
References	[1] https://pubmed.ncbi.nlm.nih.gov/28321130/ [2] https://pubmed.ncbi.nlm.nih.gov/30944253/ [3] https://pubmed.ncbi.nlm.nih.gov/31848188/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-09-04)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07667400	NOT_YET_RECRUITING	Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Paranasal Sinus Neoplasms; Nasopharyngeal Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Hypopharyngeal Cancer; Carcinoma of Larynx; Oral Squamous Cell Carcinoma; Salivary Gland Cancer; Adenoid Cystic Carcinoma; Prostate Cancer; Metastatic Castration Resistant Prostate Cancer	National Cancer Institute (NCI)	2026-09-09	PHASE1; PHASE2
NCT07322341	RECRUITING	Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8	University of Washington	2026-10-01	PHASE2
NCT07002320	RECRUITING	Metastatic Castrate-Resistant Prostate Cancer (mCRPC)	Institute of Cancer Research, United Kingdom	2025-04-28	PHASE1; PHASE2
NCT04245397	RECRUITING	Myelodysplastic Syndromes	Syntrix Biosystems, Inc.	2020-06-30	PHASE1
NCT06149481	RECRUITING	Metastatic Colorectal Cancer	National Cancer Institute (NCI)	2024-03-26	PHASE1; PHASE2
NCT05570825	RECRUITING	Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8	University of Washington	2023-04-06	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

SX-682 CXCR inhibitor

Chemical Structure

Molecular Weight: 467.20